<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1227">
  <stage>Registered</stage>
  <submitdate>23/04/2006</submitdate>
  <approvaldate>1/05/2006</approvaldate>
  <actrnumber>ACTRN12606000149561</actrnumber>
  <trial_identification>
    <studytitle>Zinc supplementation in asthma</studytitle>
    <scientifictitle>The effect of oral Zinc supplementation in asthma in reducing the dose of inhaled steroids</scientifictitle>
    <utrn />
    <trialacronym>OZSA</trialacronym>
    <secondaryid>The Queen Elizabeth Hospital Ethics Committee: 2006014</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Zinc 
50 mg Zn daily for 4 months</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in inhaled steroid dose</outcome>
      <timepoint>At 4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak expiratory flow variability</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Postbronchodilator forced expired volume in 1 second</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exhaled nitric oxide concentration</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Persistent asthma: on 400ug of budesonide or equivalent toachieve good to moderate asthma control.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prednisolone or exacerbation within 3 months :smoking in last 2 years.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>third person allocation schedule "off-site"</concealment>
    <sequence>random number by computer program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Adelaide University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Department  of Medicine, Adelaide University funds</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil at this time</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hypothesis: Zinc deficiency potentiates airway inflammation in asthma.
This study is to determine if oral zinc supplementation will improve asthma control to enable  a reduction in the maintenance dose of inhaled steroids.
Blinding is for subjects &amp; assessors.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizaeth Hospital &amp; Lyell McEwin Hspital  branch of the Central Nortern AdelaideHealth Service Ethics of Human Research Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006014</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Richard Ruffin</name>
      <address>Department of Medicine
The Queen Elizabeth Hospital Campus
Adelaide University
The Queen Elizabeth Hospital
Ward 5B
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226740</phone>
      <fax>+61 8 82226042</fax>
      <email>richard.ruffin@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Executive Officer (Currently Ms K Hoffman)</name>
      <address>Research Secretariat
The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226841</phone>
      <fax />
      <email>kelly.hoffman@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>